| Literature DB >> 27125435 |
Zhizhi Sun1, Matthew Worden2, James A Thliveris3, Sabine Hombach-Klonisch3, Thomas Klonisch3, Johan van Lierop4, Torsten Hegmann5, Donald W Miller6.
Abstract
Effective treatment of brain disorders requires a focus on improving drug permeability across the blood-brain barrier (BBB). Herein, we examined the pharmacokinetic properties of negatively charged iron oxide nanoparticles (IONPs) and the capability of using lysophosphatidic acid (LPA) to transiently disrupt the tight junctions and allow IONPs to enter the brain. Under normal conditions, IONPs had a plasma half-life of six minutes, with the liver and spleen being the major organs of deposition. Treatment with LPA enhanced accumulation of IONPs in the brain and spleen (approximately 4-fold vs. control). LPA and IONP treated mice revealed no sign of peripheral immune cell infiltration in the brain and no significant activation of microglia or astrocytes. These studies show improved delivery efficiency of IONPs following LPA administration. Our findings suggest transient disruption of the BBB may be a safe and effective method for increasing IONP delivery to the brain.Entities:
Keywords: BBB disruption; Biodistribution; Blood–brain barrier; Brain delivery; Iron oxide nanoparticles
Mesh:
Substances:
Year: 2016 PMID: 27125435 DOI: 10.1016/j.nano.2016.04.008
Source DB: PubMed Journal: Nanomedicine ISSN: 1549-9634 Impact factor: 5.307